MX2021001877A - Composiciones y métodos para el tratamiento de lesión pulmonar aguda. - Google Patents

Composiciones y métodos para el tratamiento de lesión pulmonar aguda.

Info

Publication number
MX2021001877A
MX2021001877A MX2021001877A MX2021001877A MX2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A
Authority
MX
Mexico
Prior art keywords
treatment
lung injury
compositions
methods
acute lung
Prior art date
Application number
MX2021001877A
Other languages
English (en)
Spanish (es)
Inventor
Aron B Fisher
Sheldon I Feinstein
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2021001877A publication Critical patent/MX2021001877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021001877A 2018-08-17 2019-08-15 Composiciones y métodos para el tratamiento de lesión pulmonar aguda. MX2021001877A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Publications (1)

Publication Number Publication Date
MX2021001877A true MX2021001877A (es) 2021-07-15

Family

ID=69524874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001877A MX2021001877A (es) 2018-08-17 2019-08-15 Composiciones y métodos para el tratamiento de lesión pulmonar aguda.

Country Status (11)

Country Link
US (2) US12070483B2 (https=)
EP (1) EP3836953A4 (https=)
JP (2) JP7483684B2 (https=)
KR (1) KR20210046698A (https=)
CN (1) CN112703009B (https=)
AU (1) AU2019321654B8 (https=)
BR (1) BR112021002920A2 (https=)
CA (1) CA3109798A1 (https=)
IL (1) IL280868A (https=)
MX (1) MX2021001877A (https=)
WO (1) WO2020037146A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3109798A1 (en) 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
EP4720090A1 (en) * 2023-05-26 2026-04-08 The Trustees of The University of Pennsylvania Protective agent against endothelial dysfunction

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001278864A1 (en) * 2000-06-30 2002-01-30 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
ES2486321T3 (es) * 2010-06-18 2014-08-18 Xiberscience Gmbh Péptidos como agentes activos para estabilizar barreras biológicas
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
WO2017180546A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CA3109798A1 (en) 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury

Also Published As

Publication number Publication date
US20210315964A1 (en) 2021-10-14
AU2019321654B1 (en) 2025-07-17
IL280868A (en) 2021-04-29
BR112021002920A2 (pt) 2021-05-11
KR20210046698A (ko) 2021-04-28
US20250082715A1 (en) 2025-03-13
AU2019321654A1 (en) 2021-03-18
CN112703009A (zh) 2021-04-23
JP2021534184A (ja) 2021-12-09
CN112703009B (zh) 2024-06-11
US12070483B2 (en) 2024-08-27
AU2019321654B8 (en) 2025-08-07
WO2020037146A1 (en) 2020-02-20
JP2024102207A (ja) 2024-07-30
CA3109798A1 (en) 2020-02-20
EP3836953A4 (en) 2022-06-29
JP7822065B2 (ja) 2026-03-02
JP7483684B2 (ja) 2024-05-15
EP3836953A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12021500026A1 (en) Irak degraders and uses thereof
MX2025006196A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
PH12019502915A1 (en) Immunogenic compositions
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
ZA202211980B (en) Methods and treatment of trauma
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
IL280218A (en) Methods for the treatment of HFPEF using dapagliflozin and compounds containing it
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors